Heart Failure Affects 13% of Adults with Congenital Heart Disease Despite Normal Function
Large study reveals hidden heart failure in 1 in 8 adults born with heart defects, even when heart pumping appears normal.
Summary
A major study of 4,507 adults with congenital heart disease found that 13% develop heart failure with preserved ejection fraction (HFpEF), even though their hearts pump normally. This condition occurred across all severity levels of congenital heart disease and was linked to five times higher hospitalization rates. Patients with HFpEF were older, had more diabetes and obesity, and experienced more atrial fibrillation. Despite the significant health burden, only 4% received proper heart failure diagnosis and less than 6% got modern treatments like SGLT2 inhibitors. This research highlights a major gap in recognizing and treating this condition in people born with heart defects.
Detailed Summary
Heart failure with preserved ejection fraction represents a critical but underrecognized health challenge for adults born with congenital heart defects. Unlike traditional heart failure where the heart's pumping ability is clearly impaired, HFpEF occurs when the heart muscle becomes stiff and cannot fill properly, despite maintaining normal ejection fraction.
Researchers analyzed medical records from 4,507 adults with congenital heart disease across Eastern Denmark's specialized cardiac centers. They identified HFpEF using strict criteria including preserved heart function, diuretic medication use, and elevated biomarkers or echocardiographic evidence of the condition.
The results revealed that 13% of patients had developed HFpEF, with surprisingly consistent rates across mild (13%), moderate (12%), and severe (18%) congenital heart disease categories. Patients with HFpEF were significantly older (median 60 vs 41 years) and carried substantially higher burdens of metabolic conditions including diabetes, obesity, and atrial fibrillation. Most concerning, these patients experienced nearly five times higher cardiovascular hospitalization rates.
Despite this substantial disease burden, the study exposed major treatment gaps. Only 4% of HFpEF patients had received proper heart failure diagnoses, and fewer than 6% were prescribed SGLT2 inhibitors, which represent cutting-edge treatments for this condition. This suggests widespread underrecognition and undertreatment of a serious cardiovascular complication.
For longevity and health optimization, these findings emphasize the importance of proactive cardiovascular monitoring in adults with congenital heart disease, regardless of apparent heart function. Early recognition and treatment of HFpEF could potentially prevent hospitalizations and improve long-term outcomes in this vulnerable population.
Key Findings
- 13% of adults with congenital heart disease develop heart failure despite normal heart pumping function
- HFpEF patients face 5x higher cardiovascular hospitalization rates than those with normal heart function
- Only 4% received proper heart failure diagnosis and 6% got modern SGLT2 inhibitor treatments
- Condition affects all severity levels equally, from mild to severe congenital heart disease
- HFpEF patients show higher rates of diabetes, obesity, and atrial fibrillation
Methodology
Retrospective cohort study analyzing electronic medical records from 4,507 adults with congenital heart disease across multiple specialized cardiac centers in Eastern Denmark. HFpEF was defined using preserved ejection fraction ≥50%, diuretic use, plus elevated biomarkers and/or echocardiographic evidence.
Study Limitations
Study limited to Danish population which may not represent global diversity. Retrospective design relies on existing medical records which could miss cases or contain incomplete data. Definition of HFpEF, while clinically relevant, may not capture all patients with early-stage disease.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.